Neuroendocrine tumour+1
RecruitingStudy on Aldesleukin and Dendritic Cell Vaccine for Patients with Resected Stage IV Neuroendocrine Tumors and Soft Tissue Sarcoma
Study on Aldesleukin and Dendritic Cell Vaccine for Patients with Resected Stage IV Neuroendocrine Tumors and Soft Tissue Sarcoma
- Disease:Neuroendocrine tumourSoft tissue sarcoma
- Substances:AldesleukinAutologous Tumor Lysate-Loaded Dendritic Cells
Italy- Participants:18–64 years · 65+ years
- Substances:Aldesleukin
- Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.










